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Hyperhomocysteinemia is a risk factor for Alzheimer’s disease (AD). Both homocysteine
(Hcy) and amyloid β (Aβ), which accumulates in the brain of AD patients, bind copper. Aim
of this study was to test the hypothesis that the association of Hcy and AD results from a
molecular interaction between Hcy and Aβ that is mediated by copper. We established a
microtiter plate format thioflavin T aggregation assay to monitor Aβ42 fibrillization. Copper
(5 µM) completely prevented Aβ42 (5 µM) fibrillization. Homocysteine in the absence of
copper did not impact Aβ42 fibrillization, but physiological concentrations of Hcy (10–100
µM) attenuated the inhibitory effect of copper on Aβ42 fibril formation. These results
were qualitatively confirmed by electron microscopy, which did not reveal morphological
differences. To compare the toxicity of fibrillar and non-fibrillar Aβ42 exposed to copper
or Hcy, rat primary cortical neurons were treated in vitro with 5 µM Aβ42 for 72 h. After
incubation with 5 µM Aβ42 that had been aggregating in the absence of Hcy or copper,
cell viability was reduced to 40%. Incubation with 5 µM Aβ42, in which fibril formation
had been prevented or reverted by the addition of 5 µM copper, resulted in cell viability
of approximately 25%. Accordingly, viability was reduced to 25% after incubation with 5
µM monomeric, i.e., non-fibrillized, Aβ42. The addition of Hcy plus copper to 5 µM Aβ42
yielded 50% viability. In conclusion, copper prevents and reverts Aβ fibril formation leading
rather to formation of lower order oligomers or amorphous aggregates, and Hcy reduces
these effects. Such mechanisms may explain the association of hyperhomocysteinemia
and AD, leading to novel therapeutic strategies in the prevention and treatment of this
disease.
Keywords: homocysteine, Alzheimer’s disease, copper, Aβ, cytotoxicity, primary neurons
INTRODUCTION
Alzheimer’s disease (AD) is a multifactorial neurodegenerative
condition constituting the majority of dementias. Primary feature
of AD is neuronal cell loss in the hippocampus and cerebral
cortex, areas involved in memory and cognition (Bernardo et al.,
2007; Kim et al., 2008). Histopathological characteristics are
depositions of amyloid plaques, comprising extracellular accu-
mulations of fibrillar amyloid β (Aβ)-peptide, and the formation
of intracellular neurofibrillary tangles composed of hyperphos-
phorylated tau (P-tau; Hooijmans et al., 2009; Kim and Tsai,
2009). Aβ is produced by cleavage of the amyloid precursor
protein (APP) by β-secretase (BACE-1) and γ-secretase, which
is comprised of four proteins: presenilin (PS) -1 or -2, PEN,
Aph-1 and Nicastrin. Cleavage of APP by β-secretase results in
a N-terminal soluble fragment and a C-terminal fragment that is
further cleaved by γ-secretase resulting in Aβ peptides. Missense
mutations in either APP or PS-1 can cause accumulation of Aβ
in hereditary AD. The mechanism leading to Aβ accumulation
in the majority of sporadic AD patients is unclear (Mare et al.,
2007). Extracellular aggregation of the Aβ-peptide is considered a
central and causative phenomenon of AD (Yoshiike et al., 2001;
Hooijmans et al., 2009; Zatta et al., 2009; Finder et al., 2010).
However, in AD patients, Aβ is also present in elevated amounts
within the degenerating neurons, and this may contribute to cell
death (Hasegawa et al., 2005).
In vivo Aβ has two predominant forms: Aβ1-40 and Aβ1-
42 with two additional hydrophobic residues at the carboxyter-
minus. Aβ1-40 is the main soluble species, whereas Aβ1-42 is
the predominant species found in amyloid plaques. The latter is
more toxic to neurons and is considered the most amyloidogenic
species, most likely responsible for the neuropathology in AD
(Hasegawa et al., 2005; Mare et al., 2007; Finder et al., 2010).
Amyloid β aggregation is believed to happen in phases: first, Aβ
monomers associate into soluble oligomers that then form insol-
uble oligomers (initial slow nucleation or “seeding”), generating
protofibrils, and fibrils (Finder and Glockshuber, 2007; Tõugu
et al., 2009).
Whether Aβ forms fibrils in vitro in the presence of copper
and the nature of these fibrils is currently a subject of debate.
Main question is the accelerating or preventing role of copper
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in amyloid fibril formation, and whether this role is dependent
on Cu2+ or Aβ concentration and stoichiometry. It has been
presented that sub-stoichiometric concentrations of Cu2+ accel-
erate amyloid fibril formation, and supra-stoichiometric con-
centrations of Cu2+ prevent fibrillization (Viles, 2012). There
are several studies where Cu2+ was reported to inhibit fibril
formation and rather form amorphous aggregates (Yoshiike et al.,
2001; Raman et al., 2005; Tõugu et al., 2009; Innocenti et al.,
2010). On the contrary, the opposing arguments rely mainly
on the study of Sarell et al. (2010) where the substoichiometric
levels of Cu2+ were shown to accelerate fibril formation of Aβ.
A recent study of Mold et al. (2013) addresses this dilemma
by fluorimetry and transmission electron microscopy (TEM).
In this study they show that Cu2+, independent of stoichiom-
etry, prevented the formation of ThT-positive amyloid fibrils of
Aβ42.
Amyloid plaques are composed of fibrillar Aβ, small amounts
of other proteins and transition metals like copper and zinc
(Tõugu et al., 2009). Several studies have shown that homeostasis
of the transition metals copper and zinc can greatly influence
Aβ misfolding and plaque formation. Furthermore, restoring
metal ion homeostasis dissolved Aβ plaques in mice and delayed
cognitive deficits in AD patients (Zatta et al., 2009). Thus, an
interaction between Aβ and copper may be involved in AD
pathology (Klevay, 2007a,b).
We have previously shown that homocysteine (Hcy) binds
copper, and that this may be an important mechanism of the
neurotoxicity of Hcy, as the presence of Hcy can lead to deficiency
of copper-dependent enzymes like cytochrome-C-oxidase (White
et al., 2001; Apostolova et al., 2003; Linnebank et al., 2006). Hcy
is a non-proteinogenic sulfhydryl-containing amino acid formed
as an intermediate in the metabolism of methionine (Hasegawa
et al., 2005; Bernardo et al., 2007; Kim et al., 2008). Deficiencies
of vitamin B12 or folate, common conditions in the elderly,
can lead to hyperhomocysteinemia, which is a risk factor for
cardio- and cerebrovascular diseases as well as neurodegenerative
disorders such as AD (White et al., 2001; Irizarry et al., 2005;
Linnebank et al., 2006; Bernardo et al., 2007; Kim et al., 2008). In
hyperhomocysteinemic patients, blood copper levels are elevated,
possibly due to binding to increased amounts of Hcy (Apostolova
et al., 2003; Linnebank et al., 2006). In cell culture, Hcy sensitizes
neurons to Aβ toxicity by induction of intraneuronal Aβ accu-
mulation due to speculative mechanisms (Hasegawa et al., 2005).
In addition, hyperhomocysteinemia increases Aβ production in
rats, probably through enhanced expression of γ-secretase and
APP phosphorylation, placing hyperhomocysteinemia upstream
of increased Aβ production (Zhang et al., 2009). In this study, we
aimed at modelling the interaction between copper, Hcy and Aβ
fibril formation.
MATERIALS AND METHODS
ORIGIN OF REAGENTS
All reagents were ultra pure quality and purchased from
Sigma-Aldrich (Buchs, Switzerland) unless otherwise indicated.
DL-Homocysteine was minimum 95% titration (Sigma-Aldrich).
Recombinant Aβ42 peptide was purchased as a 1,1,1,3,3,3-
hexafluoro-2-propanol (HFIP) film, and His6Ala (H6A) mutated
recombinant Aβ42 and scrambled recombinant Aβ42 as trifluo-
roaceticacid (TFA) film from rPeptide (Bogart, Georgia, USA).
Solutions were prepared in fresh MilliQ-water.
PREPARATION OF Aβ42 PEPTIDE STOCKS
To ensure homogenous preparation of the Aβ42 peptide, 1 mg of
recombinant peptide HFIP or TFA film was distributed in 50 µg
aliquots. All peptides were aliquotted with the same procedure.
After addition of 200 µL HFIP to 1 mg peptide, the solution
was shortly sonicated, transferred into a Protein LoBind tube
(Eppendorf, Hamburg, Germany), and the solvent was evapo-
rated with a constant stream of nitrogen. The peptide film was
resuspended in 1 ml of HFIP and, after short vortexing and
sonication, dispensed in 50 µg aliquots. HFIP was evaporated
under a stream of nitrogen, aliquots were snap-frozen, and stored
at −80◦C until use as described previously (Wood et al., 1996;
Stine et al., 2003).
PREPARATION OF FRESH Aβ42 WORKING SOLUTION
For assays, one Aβ42 peptide aliquot was dissolved in 44.4 µl
10 mM NaOH, pH 12, to yield a stock solution of approximately
250 µM. The aliquot was vortexed, sonicated, vortexed again
shortly, spun down and placed on ice until use. The resuspension
of the Aβ1-42 film in 10 mM sodium hydroxide was adapted from
Teplow (2006). The low NaOH concentration reassured the rapid
pH neutralization to 7.4 upon dilution into the experimental
buffer (Teplow, 2006).
The concentration of the Aβ42 solution was determined
via absorbance at λ = 280 nm measured with NanoDrop
UV/Vis spectrophotometer (NanoDrop Technologies, Wilming-
ton Delaware, USA). Concentration was calculated using a molar
extinction coefficient of ε = 1730 M−1 cm−1 (Finder et al., 2010).
THIOFLAVIN T AGGREGATION ASSAYS
To study amyloid fibril formation, 5 µM Aβ42 peptide was mixed
with 50 µM Thioflavin T (ThT) in 10 mM sodium phosphate
solution, 500 mM NaCl, and 0.1 mM HCl to a final volume of
100 µl. Different concentrations of ZnCl2, CuCl2 and Hcy were
added to selected samples after 0 or 120 min of measurement,
respectively. Samples were incubated in a flat bottom microtiter
plate, and the increase in ThT fluorescence was measured via
top-beam irradiation (λEx = 450 nm, λEm = 510 nm) with a
lamp energy of 5000 (arbitrary unit) and a counting time of
0.1 s by Berthold Mithras LB 940 (Berthold Technologies GmbH,
Regensdorf, Switzerland). Values were recorded every 2 min with
constant orbital shaking at slow speed between the measurements.
Temperature was controlled to 30◦C.
CYTOTOXICITY
Rat primary cortical neuron cultures were prepared as described
(Finder et al., 2010). Neurons were plated in Neurobasal media
(GIBCO, Invitrogen, Basel, Switzerland) with B-27 supplement
(GIBCO) and L-glutamine (GIBCO) on poly-L-ornithine pre-
coated 96-well plates at a density of approximately 10,000 cells per
well. Cultures were maintained in a humidified 7% CO2 incuba-
tor. Primary cortical neuron cultures were treated with Aβ-fibrils
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on day 6 in vitro. For cytotoxicity assessment, aggregation reac-
tions were performed with 10 times higher concentrations and
in the absence of ThT. Thioflavin T does not affect aggregation
kinetics, but influences cytotoxicity measurements (Finder et al.,
2010). Otherwise reaction parameters were as described above.
After reaching aggregation plateau (after 3 h), fibril suspen-
sions were transferred in 1:10 (v/v) ratio in relation to cell culture
medium in the wells. Final concentrations on the cells were: 5 µM
Aβ, 5 µM CuCl2 and 50 µM Hcy. Reaction mixture without
Aβ, CuCl2 or Hcy was used as negative control. Just before
treatment with diluted fibrils, half of the culture medium on
cells was aspirated and replaced with fresh Neurobasal medium.
Assays were performed minimum as triplicates. After 72 h cell
viability was quantified by a colorimetric 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT; Keskitalo et al.,
2007). Briefly, treatment medium was removed from cells and
replaced by Neurobasal medium with MTT. After incubation for
2 h, lysis buffer (10% SDS, 10 mM HCl) was added for the
incubation of cell cultures at 37◦C overnight. Absorbance was
measured on the next day (Berthold Mithras LB 940, Berthold
Technologies GmbH), and relative survival to control (reaction
mixture without Aβ, CuCl2 or Hcy) was calculated.
CELL MORPHOLOGY BY IMMUNOFLUORESCENT STAINING
Approximately 100,000 rat primary cortical neurons were seeded
in 24-well plates onto glass coverslips pre-coated with poly-L-
ornithine in water. On in vitro day 6, a 24 h-incubation with
the 1:10 diluted fibrils was started. As in the MTT-assay, aggre-
gation reactions were performed with 10 times higher reaction
concentration and without ThT, half of the culture medium on
cells was aspirated just before adding the aggregates. Due to the
aggregation assay results and the physiologically occurring Hcy
levels, we chose samples incubated with 5 µM Aβ, 5 µM CuCl2
and 50 µM Hcy to be shown in the results. Cells were stained
minimum as duplicates. 5 µM non-fibrillar Aβ42 was used as a
control.
After incubation with the fibrils the cells were fixed for 15 min
at room temperature with 4% paraformaldehyde in PBS. The cov-
erslips were rinsed with PBS, and washed three times with 0.05%
Triton X-100 in TBS for 10 min each. After blocking with 5% goat
serum (Millipore, Zug, Switzerland), 5% horse serum (GIBCO)
and 0.2% Triton X-100 in TBS for 60 min, the coverslips were
incubated with primary antibodies in blocking buffer (anti-MAP2
1:1500, Synaptic Systems, Germany; 1:100 anti-human APP 6E10,
Covance, Princeton, New Jersey, USA) in a humidified chamber
overnight at 4◦C. On the following day coverslips were washed
three times with 0.05% Triton X-100 in TBS for 10 min each,
blocked for 30 min at room temperature in blocking solution, and
incubated with 1:300 diluted secondary antibodies (anti-rabbit
Alexa488 (Invitrogen) and anti-mouse Cy3 (Jackson ImmunoRe-
search, West Grove, Pennsylvania, USA)) in blocking buffer for
2 h at room temperature. After washing, cell nuclei were stained
with 2-(4-amidinophenyl)-1H-indole-6-carboxamidine (DAPI),
and coverslips were mounted on glass slides with Hydromount
(Chemie Brunschwig, Basel, Switzerland). Staining was exam-
ined using a Zeiss ImagerZ1 microscope (Zeiss, Oberkochen,
Germany). All images were taken with a 20× objective.
NEGATIVE-STAIN ELECTRON MICROSCOPY OF AGGREGATES
Aliquots of the aggregation reactions without ThT were analyzed,
when plateau was readily reached after 4 h agitation at 30◦C. 3 µl
of each sample was adsorbed to 300 mesh carbon-coated copper
grids for 1 min and stained with 2% uranyl acetate in water for
15 s three times. After staining grids were washed with water and
allowed to dry before TEM. TEM was performed on a Philips CM
12 microscope at 100 MeV.
STATISTICS
Statistical analysis was run using IBM SPSS Statistics 20 (IBM,
Armonk, New York, USA), and significance was calculated using
one-way ANOVA with Bonferroni’s post hoc test for multiple
comparisons. Statistical significance was considered as p< 0.05.
All experiments were repeated three times with n ≥ 3 samples
for each experimental condition.
RESULTS
HOMOCYSTEINE AND Aβ42 COMPETE FOR CuCl2, BUT NOT FOR ZnCl2,
IN ThT AGGREGATION ASSAY
We established a microtiter plate format ThT aggregation assay
for fast and reproducible monitoring of Aβ42 fibrillization in
the presence of Hcy and the transition metals copper and zinc.
As previously reported, copper and zinc inhibited the formation
of ThT reactive beta-sheet structures of Aβ (Yoshiike et al.,
2001; House et al., 2004). In our experiments ZnCl2 reduced
Aβ42 fibrillization by extending the lag phase, slightly decreas-
ing the slope, and diminishing the final plateau (Figure 1A).
CuCl2 (5 µM) completely prevented Aβ42 (5 µM) fibrilliza-
tion (Figure 1A). Homocysteine alone at increasing concen-
trations had no effect on Aβ fibril formation (Figure 1B),
but concentration-dependently reduced the inhibitory effect of
CuCl2 on Aβ42 fibrillization (Figure 1C). No such interaction
on Aβ42 aggregation was observed between Hcy and ZnCl2
(Figure 1D).
HOMOCYSTEINE DOES NOT ALTER Aβ42 FIBRIL MORPHOLOGY
To decide whether Hcy or copper have qualitative effects on Aβ
aggregation, we analyzed the morphology of the aggregates of
5 µM Aβ42, 5 µM Aβ42 plus 50 µM Hcy and 5 µM Aβ42
plus 5 µM CuCl2 by TEM after 4 h aggregation (Figure 2).
TEM images confirmed the observations from ThT aggregation
assays that Hcy alone does not alter Aβ42 fibrillization, as the
Aβ42 fibrils formed in the presence of Hcy were alike to fibrils
formed without Hcy showing a high number of mature fibrils
(Figures 2A,B). In the presence of CuCl2, only few aggregates were
found with decreased fibril length and complexity (Figure 2C).
TOXICITY OF Aβ42 FIBRILS IS INCREASED IN THE PRESENCE OF CuCl2
AND DECREASED IN THE PRESENCE OF HOMOCYSTEINE OR
HOMOCYSTEINE PLUS CuCl2
To be able to conclude whether cytotoxicity of mixtures of cop-
per, Hcy and Aβ is caused by changes in the fibrillar status of
Aβ42, we examined the cytotoxic effects of CuCl2, Hcy and the
two together without Aβ42 (Figure 3A). Rat primary cortical
neurons were treated on day 6 in vitro for 72 h with increasing
concentrations of CuCl2 (0.5–5.0 µM), Hcy (5–50 µM) or CuCl2
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FIGURE 1 | Effect of metal ions and homocysteine (Hcy) on Aβ42
fibrillization as observed in ThT-assay. Fibrillization of 5 µM Aβ42 (light
gray) in the presence of (A) 5 µM ZnCl2 (light blue) or 5 µM CuCl2 (light
green), (B) increasing concentrations of Hcy (5 µM—red, 10 µM—orange,
25 µM—dark green, 50 µM—pink, and 100 µM—dark blue), (C) 5 µM Hcy
(red) or 5 µM CuCl2 (light green), or 5 µM CuCl2 together with increasing
Hcy concentration (10 µM—orange, 25 µM—dark green, 50 µM—pink,
and 100 µM—dark blue), and (D) 5 µM Hcy (red) or 5 µM ZnCl2 (light
blue), or 5 µM ZnCl2 together with increasing Hcy concentration (25
µM—dark green, 50 µM—pink, and 100 µM—dark blue). All components
were added to the reaction mixture directly at the beginning of the
fibrillization reaction.
FIGURE 2 | Visualization of Aβ42 fibrils. 110,000x transmission electron
microscopy images of the end point products of Aβ42 fibrillization after 4
h of aggregation at 30◦C. (A) 5 µM Aβ42 alone, (B) 5 µM Aβ42 + 50 µM
Hcy and (C) 5 µM Aβ42 + 5 µM CuCl2. Aβ42, Hcy and CuCl2 were all
added at the beginning of the ThT-assay. Scale bar represents
100 nm.
plus Hcy in incubation mixtures previously incubated for 4 h
at 30◦C. No significant toxicity was observed in neurons treated
with the selected concentrations of CuCl2 or Hcy alone. In line
with previous results, the co-incubation of Hcy plus CuCl2, i.e.,
with homocysteine/copper-complexes, showed a concentration-
dependent toxicity (White et al., 2001; Linnebank et al., 2006).
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FIGURE 3 | Cell viability and morphology of rat primary cortical
neurons after treatment with CuCl2 and Hcy in the absence or
presence of Aβ42. Aggregations for viability and morphology studies
were performed identically to previous aggregation assays, but lacking
ThT due to its cytotoxicity. After 4 h agitation, samples were
subsequently collected for the assessments. (A) Primary neurons were
incubated for 72 h with increasing µM concentrations of CuCl2 (dark
gray), CuCl2 + Hcy (light gray), or Hcy (stripes) without Aβ42, to study
their individual cytotoxicity. Control sample (aggregation assay reaction
mixture) is visualized in the white column. (B) Effect of CuCl2 and Hcy on
Aβ42-induced toxicity. 5 µM Aβ42; 5 µM Aβ42 + 5 µM CuCl2; 5 µM Aβ42
+ 5 µM CuCl2 + 50 µM Hcy; 5 µM Aβ42 + 50 µM Hcy were incubated on
the cells for 72 h. As controls non-fibrillar 5 µM Aβ42 (MonoAb) and
aggregation assay reaction mixture without Aβ42 were used. All values
are relative to reaction mixture control sample ± S.D. (C)
Immunofluorescent staining of primary cortical neurons after 24 h
incubation. Antibody against neuronal marker, MAP2 (green), visualizes
the changes of neuronal morphology; whereas anti-human APP (red)
shows the Aβ aggregates and DAPI (blue) the cell nuclei. Concentrations
were as indicated in (B). Scale bar represents 100 µm.
Next we studied the toxicity of Aβ42 fibrils formed in the
presence of CuCl2, Hcy or both (Figure 3B). Viability of primary
neurons decreased to 40% after 72 h incubation with 5 µM Aβ42
forming fibrils alone. Additional presence of 50 µM Hcy or 5
µM CuCl2 plus 50 µM Hcy resulted in a slightly higher viability
of 50%. 5 µM Aβ42 incubated in the presence of 5 µM CuCl2
showed a significant increase in toxicity reducing cell viability to
25%. The same viability was observed after incubation with 5 µM
monomeric Aβ. This shows that most likely CuCl2 induces the
formation of lower order oligomers or amorphous aggregates of
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Aβ that have high cytotoxicity, whereas Hcy diminishes this effect
and does not obviously contribute to cytotoxicity itself under the
selected experimental conditions.
Observations from cytotoxicity studies were confirmed by
morphological analysis of neurons treated with Aβ42 aggregates
collected after 4 h of aggregation without ThT (Figure 3C). Cells
incubated with 5 µM Aβ42 plus 5 µM CuCl2 were shrunken
and presented fewer neurites, resembling the morphology of
cells treated with 5 µM monomeric Aβ42. In both, Aβ42 plus
CuCl2 and monomeric Aβ42 treated cells, also anti-APP staining
patterns were similar visualizing fewer and smaller amyloid
plaque-like structures. Aβ42-stainings in other treatment condi-
tions were similar to each other. Vehicle (without Aβ42) serving
as a negative control for anti-APP staining showed no such effects.
CuCl2 HAS LIMITED EFFECTS ON THE AGGREGATION OF H6A MUTATED
Aβ42
Fibrillization of His6Ala-mutated Aβ42 (H6A), which has low
affinity to copper (Sacco et al., 2012), was studied to examine
the specificity of copper induced inhibition of Aβ42 aggregation.
Homocysteine only caused a minor concentration-dependent
reduction in the maximum of ThT fluorescence in H6A fibril-
lization, which might have been due to unspecific variation in
the ThT signal (Figure 4A). At Hcy concentrations higher than
50 µM, aggregation curves remained unchanged. Addition of
5 µM CuCl2 to the aggregation reaction containing 5 µM H6A
inhibited its fibrillization leading to a longer lag phase, a decreased
slope and plateau. Nonetheless, CuCl2 was not able to completely
prevent H6A fibrillization (Figure 4B). The effect of CuCl2 on
H6A was thus decreased compared to its effects on wild-type
peptides. Increasing concentrations of Hcy (10–100 µM) in the
aggregation reaction of 5 µM H6A plus 5 µM CuCl2 reversed
the inhibitory effect of CuCl2 on H6A fibrillization (Figure 4B).
The concentration of Hcy needed to restore H6A fibril formation
was smaller than in the case of wild-type Aβ42. As H6A has a
lower affinity to copper than Aβ42, this underscores that there
is a competition in binding of copper between Aβ42 and Hcy
as underlying mechanism of the interaction of Hcy and copper
FIGURE 4 | Fibrillization of H6A mutated Aβ42 and scrambled Aβ42 in
ThT-aggregation assay, and their cytotoxicity in rat primary cortical
neurons. Fibrillization of 5 µM H6A mutated Aβ42 (H6A; light blue) (A) in
the presence of increasing concentrations of Hcy (10 µM—orange, 25
µM—dark green, 50 µM—pink, and 100 µM—dark blue), (B) with 5 µM
CuCl2 and increasing concentrations of Hcy (10 µM—orange, 25
µM—dark green, 50 µM—pink, and 100 µM—dark blue). (C) 5 µM
scrambled Aβ42 (ScAβ; light blue) does not form fibrils when incubated
alone or together with 5 µM CuCl2 or 5 µM CuCl2 + 50 µM Hcy or 50 µM
Hcy. (D) Cell viability of rat primary neurons after 72 h incubation with
H6A fibrils or ScAβ incubated under same conditions. Samples from
aggregation assay without ThT, but with CuCl2, Hcy or both, were
collected at the plateau after 4 h incubation. Concentrations were 5 µM
H6A or ScAβ; 5 µM H6A or ScAβ + 5 µM CuCl2; 5 µM H6A or ScAβ + 5
µM CuCl2 + 50 µM Hcy; 5 µM H6A or ScAβ + 50 µM Hcy. As a control
non-fibrillar 5 µM H6A or ScAβ (Mono) and aggregation assay reaction
mixture without H6A or ScAβ were used. All values are relative to
reaction mixture control sample ± S.D.
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FIGURE 5 | Aβ42 fibrils untangle by addition of CuCl2 at timepoint 120
min in ThT aggregation assay. (A–C) CuCl2 was added at the point
indicated by an asterisk. (A) Addition of 5 µM CuCl2 caused a drastic
reduction in ThT fluorescence when added to an aggregation reaction of 5
µM Aβ42 (dark green). Water, in equal volume, (H2O, dark gray) did not
induce reduction in ThT fluorescence. As controls, aggregation of 5 µM
Aβ42 (light gray) and 5 µM Aβ42 + 5 µM CuCl2, added at the beginning of
the reaction (light green), are shown. (B) When Aβ42 fibrils are formed in
the presence of 15 µM Hcy (orange), their untangling after CuCl2 addition
depends on the molar ratio between CuCl2 and Hcy (5 µM CuCl2—light
green and 15 µM CuCl2—dark green). Water added in equal volumes to
CuCl2 did not change ThT fluorescence (light and dark blue). As a control
aggregation of 5 µM Aβ42 (light gray) is shown. (C) After CuCl2 addition
Aβ42 fibrils that were previously formed in high Hcy concentration (5 µM
Aβ42+ 50 µM Hcy) untangled. Degree of untangling was dependent on the
molar ratio of Aβ42 to added CuCl2 and on the molar ratio of Hcy to added
CuCl2 concentration (5 CuCl—light green, 15 µM CuCl2—dark green, 20
µM CuCl2—purple, 25 µM CuCl2—light pink, 30 µM CuCl2—light blue, and
50 µM CuCl2—dark blue). (D) Water addition at timepoint 120 min did not
induce changes in the ThT fluorescence of the reactions of 5 µM Aβ42 + 50
µM Hcy. Water was added in equal volumes as CuCl2 in panel (C).
on Aβ fibrillization. The increase in ThT fluorescence is specific
to the formation of cross-pleated β-sheets. Accordingly, ThT
fluorescence of incubation mixtures containing scrambled Aβ42
(ScAβ), a peptide derivative of Aβ42 that does not form fibrils, did
not differ after addition of either 5 µM CuCl2, or 50 µM Hcy or 5
µM CuCl2 plus 50 µM Hcy confirming that the above described
results did not result from artefacts induced by Hcy or copper in
the incubation mixtures (Figure 4C).
TOXICITY OF Aβ42, H6A AND ScAβ TO PRIMARY CORTICAL NEURONS
In primary neuron cultures, fibrils of 5 µM H6A, formed either
in the absence or presence of 5 µM CuCl2, 50 µM Hcy, or a
combination of both, each reduced cell viability to approximately
60% after 72 h incubation (Figure 4D). Viability of neurons
treated with 5 µM ScAβ, incubated in the absence or presence
of 5 µM CuCl2, 50 µM Hcy or both, remained at approximately
90%. The overall toxicity of the H6A was significantly higher than
the one of ScAβ, but lower than of Aβ42.
ADDITION OF CuCl2 TO ALREADY AGGREGATED SAMPLES UNTANGLED
Aβ42 FIBRILS
To study whether copper supplementation could be used to revert
aggregation, we performed a simple aggregation assay in which
CuCl2 was added to an already fibrillized sample of either Aβ42
alone or of Aβ42 incubated in the presence of 15 µM or 50 µM
Hcy. We selected these Hcy concentrations as they define the lower
range of Hcy plasma concentrations in mild and intermediate
hyperhomocysteinemia, respectively (Stanger et al., 2009).
The addition of 5 µM CuCl2 to a sample of 5 µM Aβ42
at time point 120 min drastically reduced ThT fluorescence,
indicating untangling of Aβ42 fibrils (Figure 5A) similar to the
preventive effect of copper on fibrillization (Figure 2C). Only a
minor reduction in ThT fluorescence was observed after addi-
tion of an equal volume of water (vehicle in which copper had
been dissolved) to already fibrillized 5 µM Aβ42 at the same
time point as negative control (Figures 5A,B). After addition of
increasing CuCl2 concentrations (5–15 µM), Aβ42 fibrils that
had formed in the presence of 15 µM or 50 µM Hcy also
untangled (Figures 5B,C). The decrease in ThT fluorescence
depended on the ratio between copper and Hcy (Figures 5B,C).
ThT fluorescence remained unchanged after vehicle additions
(Figure 5D).
DISCUSSION
Hyperhomocysteinemia is a risk factor for AD, in which Aβ
fibrillization plays an important role. Our study suggests that
copper is a link between Hcy and Aβ. First, via a ThT assay and
TEM, we confirmed that in vitro CuCl2 prevents and reverts Aβ
fibril formation (House et al., 2004; Bolognin et al., 2011; Chen
et al., 2011; Figures 1A–C, 5A–C). Addition of CuCl2 results in
decreased Aβ fibril length and complexity i.e., lack of higher order
aggregates (Figure 2C). The underlying mechanism is most likely
connected to the ability of CuCl2 to prevent the formation of
Aβ42 beta-sheets in vitro (Yoshiike et al., 2001; House et al., 2004),
but due to the nature of ThT assay we cannot completely rule
out the possibility of the formation of oligomers or amorphous
aggregates. However, Hcy did not affect the fibrillar structure of
Aβ as seen in ThT assay and in TEM images (Figures 1B, 2B).
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Our ThT aggregation assay results of CuCl2 and Aβ are in-
line with other published results with similar experimental setup.
It has been presented that in experimental conditions where
fibril formation is fast, metal ions lower concentration of free
peptide and thus inhibit fibrillization (Tõugu et al., 2009). In
conditions with slow fibril formation metal ions enhance fib-
ril formation by metal-induced aggregates that can turn into
fibrils (Sarell et al., 2010). Differences in experimental setup
are also greatly influencing the outcome of fibrillization stud-
ies. This is summarized in a recent publication by Viles (2012)
and shows multiple differences associated with changes in sto-
ichiometry, used peptide preparation, concentration and study
technique.
Cytotoxicity experiments performed in the absence of Aβ42
showed that CuCl2 or Hcy alone had no effect on cell viability
(Figure 3A). In accordance to previous studies, cytotoxicity was
elevated when cells were co-incubated with CuCl2 and Hcy,
confirming the toxicity of Hcy-copper-complexes (Figure 3A;
White et al., 2001). In accordance with our ThT assay data and
TEM images, toxicity of mature Aβ42 fibrils to primary neurons
was high, and Aβ fibrils formed in the presence of Hcy and
CuCl2 showed similar toxicity (Figures 1C, 2A–C, 3B,C). Aβ42
co-incubated in 1:1 molar ratio with CuCl2 showed the same level
of toxicity as monomeric Aβ42 underlining that CuCl2 effectively
inhibited the formation of bigger, more mature fibrils during ThT
aggregation assays (Figures 2C, 3B; House et al., 2004; Chen et al.,
2011). Is has been reported that the fibrillar status of Aβ42 affects
its cytotoxicity in cultured neurons: small soluble Aβ42 dimers
and oligomers cause higher toxicity than bigger fibrillar forms
(Klyubin et al., 2005; Lesné et al., 2006; Agnati et al., 2007; Ferreira
et al., 2007; Haass and Selkoe, 2007; Ono et al., 2009).
As a certain time-span is required for Aβ preparations in
contact with primary neurons to exert the cytotoxic properties,
we cannot completely rule out that during the 72 h incubation
a modification of the Aβ species can occur. However, as a result
of our Aβ ThT aggregation assays we observed that the addi-
tion of CuCl2 almost completely prevented the formation of
higher order aggregates (sensitive to ThT fluorescence). As CuCl2
itself did not have a measurable influence on cell viability, we
infer that the observed cytotoxicity is due to Aβ monomers and
potentially aggregates of lower molecular weight, such as Aβ di-
and oligomers, Aβ-derived diffusible ligands or protofibrils (all
probably being ThT fluorescence negative) that may have formed
during the incubation period.
Copper has four coordinating ligands in human Aβ: 3N and
1O, which involve His6, His13, His14 and possibly Tyr10, car-
boxylate group of Asp1, the amide of Ala2, and the N-terminal
amine. To date, no consensus of exact coordinating ligands
exists. When single histidines were mutated to alanine, Hong
et al. (2010) observed that His6 has three times higher copper
binding constant than His13 or His14. His6 also requires less
conformational changes upon copper binding, making it more
entropy-favored. His6 was concluded to be ubiquitously involved
in copper binding, accounting for 50% of the Aβ bound Cu(II).
In our experiments, Hcy had only minor effect on the fibril
formation of H6A mutant of Aβ42 with reduced affinity to
copper (Figure 4A). Also the effect of CuCl2 was weaker in H6A
fibrillization, and the concentration of Hcy needed to restore
H6A fibril formation was reduced compared to wild type Aβ42
(Figures 4B, 1C). This allows the speculation that the amount
of mature fibrils i.e., higher order aggregates in this sample
was higher compared to the wild type Aβ42. In accordance to
this, H6A fibrils also showed less pronounced cytotoxicity in the
presence of CuCl2 (Figure 4D). The control, ScAβ, expectedly
showed no fibrils in ThT-assay (Figure 4C). Accordingly, ScAβ
was not cytotoxic and this was not influenced by incubation
with CuCl2 or CuCl2 plus Hcy (Figure 4D). In ScAβ the copper
binding sites are lost, confirming that binding of copper to Aβ was
the decisive mechanism for the observed differences in the ThT
assay and the cytotoxicity experiments of the different combina-
tions.
The addition of CuCl2 to already fibrillized Aβ led to untan-
gling of fibrils (Figures 5A–C). This does not necessarily mean
that copper is relevant for Aβ fibrillization in vivo, however, mice
with defective copper transport have decreased brain copper levels
together with increased amounts of amyloid plaques. When these
mice are crossed with Wilson’s disease mouse model, the offspring
have increased brain copper levels, less amyloid plaques and a
longer life span (Phinney et al., 2003). When copper sulphate was
added to the drinking water of mice susceptible to amyloid accu-
mulation, less accumulation was observed (Bayer et al., 2003).
In patients with mild to moderate AD, plasma copper negatively
correlates with cognitive abilities (Pajonk et al., 2005; Kessler et al.,
2006). In addition, AD patients show elevated serum levels of free
copper (serum copper not bound to ceruloplasmin) (Squitti et al.,
2004, 2005, 2006, 2009, 2011; Capo et al., 2008) while autopsy
samples of hippocampus and amygdala from AD patients showed
generally reduced copper contents (Deibel et al., 1996; Klevay,
2008).
In contrast, in the amyloid plaques, copper concentration can
be as high as 400 µM, although normal brain extracellular con-
centration is 0.2–1.7 µM (Gutteridge, 1984; Kardos et al., 1989;
Linder and Hazegh-Azam, 1996; Lovell et al., 1998; Schümann
et al., 2002; White et al., 2004; Squitti et al., 2006). This data
seems to be in contrast to our observation that CuCl2 prevents
amyloid fibril formation. However, in our experiments, CuCl2
alone prevented and reverted aggregation, whereas Hcy plus
CuCl2 did not. Thus, it would be interesting to analyze whether
copper in amyloid plaques of AD patients is bound to Hcy or
other molecules. Moreover, the inhibitory effect of CuCl2 on
fibrillization was concentration-dependent (Figures 5B,C). Thus,
one may speculate that in the copper-rich plaques of AD patients,
copper levels may not have reached the necessary concentration.
Serum Hcy concentrations over 14 µM are an independent
risk factor for the development of AD (Seshadri et al., 2002).
In our study, the addition of Hcy alone did not change Aβ42
fibril formation (Figure 1B), although the addition of Hcy
slightly reduced Aβ42 toxicity in vitro (Figure 3B). In co-
incubation experiments, Hcy concentration-dependently
reduced the inhibitory effects of CuCl2 on Aβ42 fibrillization
suggesting that Hcy and Aβ compete for copper binding, i.e.,
homocysteine-bound copper has reduced or no effects on Aβ42
fibril formation (Figure 1C). Two different complexes are possible
between Hcy and copper, showing molar ratios of 1:1 or ≤1:3
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(Apostolova et al., 2003). Similarly, the majority of the copper-Aβ
complexes form with a 1:1 stoichiometry at physiological pH
(Karr et al., 2005; Syme and Viles, 2006; Tõugu et al., 2008;
Faller and Hureau, 2009). For H6A, Hcy was more effective in
neutralizing the effect of CuCl2 on fibril formation confirming
that CuCl2 is less effective in preventing fibrillization of this
mutated peptide due to its reduced affinity to copper (Figure 4B).
In summary, this study shows that both Hcy and Aβ42 bind
and compete for copper. Copper prevents and reverts fibril
formation by binding to Aβ42 and thereby increases Aβ tox-
icity. Homocysteine builds toxic complexes with copper and
concentration-dependently prevents the effects of copper on Aβ42
fibrillization. In the presence of Aβ42, neurotoxicity of copper is
reduced giving rise to the speculation that one physiological Aβ
function might be the prevention of copper neurotoxicity. Due to
complex building, hyperhomocysteinemia reduces the availability
of free copper, which in the light of our results, likely increases
amyloid plaque formation. Acute presence of high copper con-
centrations untangle aggregates leading to high concentrations
of mono- or oligomeric Aβ42-copper complexes causing marked
neurotoxicity. The analysis of the interaction between Aβ42, cop-
per and Hcy in patients may lead to novel therapeutic strategies
in the prevention and treatment of AD.
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